Clinical Trials
8 trialsNCT05143840 2026-06-02
ALERTCML
University of Alabama at Birmingham
Phase 2 Recruiting
NCT03874858 2026-04-02
DANTE
Novartis
Phase 2 Completed
NCT06368414 2026-04-02
AsterA
Korean Society of Hematology
Phase 2 Recruiting
NCT04666259 2025-10-16
AIM4CML
Novartis
Phase 3 Completed
NCT05384587 2025-10-14
ASC2ESCALATE
Novartis
Phase 2 Active not recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT07091019 2025-07-29
ASC4REAL-2
Novartis
Not yet recruiting
NCT06409936 2025-07-08
PEARL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Recruiting